Explore by Category

Clinical Trial: Smoldering Myeloma Personalized Vaccine at MD Anderson

CLINICAL TRIALS - February 06, 2020

Could a vaccine prevent smoldering myeloma from progressing to active myeloma? An early Phase I clinical trial at MD Anderson Cancer Center is developing a pers... Read More

ASH 2019:  Thank you Daratumumab: The Era of Four Drug Upfront Therapy for Newly Diagnosed Patients Has Arrived

CLINICAL TRIALS - December 17, 2019

On the final day of ASH there were many presentations of four-drug studies where daratumumab has been added to backbone triplets for newly diagnosed, transplant... Read More

IMW 2019: The New GSK Antibody Drug Conjugate in Myeloma

CLINICAL TRIALS - October 02, 2019

An antibody drug conjugate is a type of immunotherapy being explored in multiple myeloma. Glaxo-Smith Klein is developing a new antibody drug conjugate in myelo... Read More

IMW 2019: A Vaccine to Extend Myeloma Remissions with Syed Abbas Ali, MD

CLINICAL TRIALS - September 19, 2019

When should myeloma vaccines be used for patients? Dr. Syed Abbas Ali, MD of Johns Hopkins Medicine tells us that it's usually when there is a low tumor burden,... Read More

IMW 2019: Amrita Krishnan, MD on the Best Myeloma Maintenance Approach After Transplant

CLINICAL TRIALS - September 19, 2019

What is the best approach for maintenance therapy? How long should patients be on maintenance? Can I stop treatment if I'm minimal residual disease (MRD) negati... Read More

Clinical Trial: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

CLINICAL TRIALS - June 28, 2019

This open-label, Phase 2 study is studying whether the monoclonal antibody Avelumab, in combination with radiation therapy, is safe in the treatment of relapsed... Read More

Clinical Trial: Daratumumab, Ixazomib, and Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

CLINICAL TRIALS - May 23, 2019

A phase II study is open evaluating how well daratumumab, ixazomib, and dexamethasone work with or without bortezomib in treating patients with newly diagnosed ... Read More

Clinical Trials: CD38 Targeted CAR T Now Open in Phase I Multiple Myeloma Study

CLINICAL TRIALS - May 17, 2019

Different targets are being used in myeloma for CAR T therapy and researchers have not yet identified the optimal target for each myeloma patient. The first tar... Read More

Clinical Trial: Reducing Insomnia of Cancer Survivors with Yoga vs. Health Education and Cognitive Behavioral Therapy

CLINICAL TRIALS - March 28, 2019

How can myeloma patients sleep better when living with cancer? A new phase III study is comparing three groups: yoga, survivorship health education and cognitiv... Read More

Clinical Trial: Using a Vaccine PVX-410 with Citarinostat +/- Lenalidomide for Smoldering Multiple Myeloma

CLINICAL TRIALS - March 08, 2019

A Phase I study of a vaccine called PVX-410 for patients with moderate/high risk Smoldering Multiple Myeloma is open. PVX-410 is a multi-peptide vaccine that ... Read More

Clinical Trial: Overall Survival Lengthened for Relapsed/Refractory Myeloma Patients Using CLR 131 Cancer-Targeted Therapy

CLINICAL TRIALS - February 02, 2019

Myeloma patients who had relapsed after receiving both a proteasome inhibitor (like Velcade) and immunomodulator (like Revlimid) participated in a Phase I study... Read More

Clinical Trial: GVAX Vaccine with Revlimid To Extend Remission

CLINICAL TRIALS - January 23, 2019

A new GVAX vaccine is being used in a clinical trial for myeloma patients who have achieved good responses to therapy. The goal of the trial is to extend remiss... Read More

Quad Therapy Clinical Trial Open for Relapsed Multiple Myeloma Using a Virus, Checkpoint Inhibitor, Carfilzomib and Dex

CLINICAL TRIALS - January 16, 2019

The destructive nature of viruses is now being applied to kill cancer cells. A new immuno-oncoloytic virus called pelareorep (Reolysin) is now being tested in a... Read More

Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies